- Nov 09 2016
Dr. Shepard, CMO of PDS Biotechnology, to Present PDS0101 Phase I/IIA Clinical Data at the Society for Immunotherapy of Cancer Meeting on November 11, 2016
November 08, 2016: PDS Biotechnology announced today that Dr. Robert Shepard, MD, Chief Medical Officer, will present data from PDS’s recently completed Phase I/IIA clinical trial with its lead cancer immunotherapy, PDS0101 at the 31st Annual Meeting of the Society for Immunotherapy of Cancer (SITC). PDS0101 is being developed to treat HPV-induced cancers, including Cervical, Anal and Head and Neck cancers. The meeting is being held at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.